Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 5/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2113063 | 0.86 | AR (0.56) | ARL3MBTL1MEN1KMT2AKDM4E | |
| SCHEMBL2113065 | 0.86 | AR (0.56) | ARL3MBTL1MEN1KMT2AKDM4E | |
| SCHEMBL14273995 | 0.84 | PDK1 (0.57) | ARL3MBTL1 | |
| SCHEMBL2112168 | 0.82 | PDK1 (0.61) | ARL3MBTL1MEN1HTTKMT2A | |
| SCHEMBL2112169 | 0.82 | PDK1 (0.61) | ARL3MBTL1MEN1HTTKMT2A | |
| SCHEMBL18086475 | 0.80 | L3MBTL1 (0.59) | POLBL3MBTL1TDP1MEN1HTT | |
| SCHEMBL30620909 | 0.78 | MMP8 (0.55) | ARPOLBL3MBTL1MEN1KMT2A | |
| SCHEMBL4110532 | 0.77 | L3MBTL1 (0.83) | POLBL3MBTL1TDP1MEN1KMT2A | |
| SCHEMBL2112345 | 0.77 | PDK1 (0.56) | ARL3MBTL1MEN1KMT2A | |
| SCHEMBL14252941 | 0.76 | AR (0.74) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158828-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-20090062341-A1 | Nuclear receptor binding agents | GTX, INC | 2009-03-05 | — | — | US | disclosed |
| US-20070265296-A1 | Nuclear receptor binding agents | GTX, INC. | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265296-A1 | Nuclear receptor binding agents | GPER1, ESRRG, ESR2 | AR 18/4885POLB 4082/4885L3MBTL1 3608/4885 |
| US-20090062341-A1 | Nuclear receptor binding agents | GPER1, ESRRG, ESR2 | AR 18/4885POLB 4082/4885L3MBTL1 3608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.